Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

39 results about "Neutralizing epitope" patented technology

Monoclonal antibody of bovine coronavirus S2 protein and epitope and application thereof

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of bovine coronavirus S2 protein, an epitope of the monoclonal antibody and application of the epitope. The invention provides a hybridoma cell strain (preservation number: CCTCC (China Center For Type Culture Collection) NO: C202510). The cell strain can secrete a monoclonal antibody which is targeted and combined with bovine coronavirus S2 protein; the amino acid sequence of the epitope identified by the monoclonal antibody is shown as SEQ ID NO: 1. Experiments prove that the monoclonal antibody has neutralizing activity, and the targeting epitope of the monoclonal antibody is a key neutralizing epitope. The invention provides a new strategy and tool for antibody drug and vaccine research and development as well as diagnosis and detection of the bovine coronavirus.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

Reconstructed respiratory syncytial virus F protein trimer

The invention discloses a reconstructed respiratory syncytial virus F protein trimer, relates to the technical field of genetic engineering vaccines, and designs an RSV F protein trimer, a monomer of the trimer does not contain a p27 sequence, and a furin enzyme digestion peptide fragment aa110-aa136 is deleted; the F2 structural domain and the F1 structural domain are connected through a GS connexon; the invention also designs point mutation combinations, and the point mutation combinations can form an inter-chain disulfide bond, so that covalent connection of the trimer is realized, and the problem of depolymerization of the trimer is fundamentally solved; the trimer is stabilized in a pre-F state, a post-F sample structure does not exist, and an ELISA result shows that a neutralizing epitope is completely reserved; the trimer antigen structure is challenged by adopting a thermal acceleration experiment method, and a result shows that the purity of the trimer antigen reaches 95% or above after the trimer antigen is placed at 37 DEG C for 28 days, and the trimer antigen is very good in stability; when the trimer is used for preparing the vaccine, the standard required by laws and regulations can be met without freeze-drying.
Owner:BEIJING LUZHU BIOTECH +1

RSV pre-F tripolymer protein combination and application thereof in preparation of bivalent RSV vaccine

The invention discloses an RSV pre-F tripolymer protein combination and application thereof in preparation of bivalent RSV vaccines, and relates to the technical field of human vaccines. The vaccine is prepared by mixing an RSV-A subtype pre-F tripolymer protein and an RSV-B subtype pre-F tripolymer protein in equal mass, and matching with an aluminum hydroxide adjuvant with the concentration of 0.35 mg / 0.5 mL. A p27 fragment and a C-terminal esterification region of each of the two F proteins are deleted, the two F proteins are connected with F2 / F1 through GSGSGS, inter-chain disulfide bonds are introduced to S146C / N460C and A149C / Y458C sites respectively, intra-chain disulfide bonds are introduced to S155C / S290C sites respectively, and stable pre-F trimers are spontaneously assembled after secretion expression of CHO cells; the vaccine does not need to be freeze-dried, still keeps high purity and neutralizing epitope integrity after being stored at 37 DEG C for 28 days, can obviously induce neutralizing antibody and T cell immunity, and can be used for preventing various RSV-A / B infections.
Owner:BEIJING LUZHU BIOTECH

Monoclonal antibody combined with multi-branch H5Nx subtype avian influenza virus HA protein in broad spectrum and application

The invention discloses a monoclonal antibody in broad-spectrum combination with multi-branch H5Nx subtype avian influenza virus HA protein and application of the monoclonal antibody. The monoclonal antibody is named as 1G10, belongs to an IgG1 subclass and comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 of which the amino acid sequences are respectively shown as SEQ ID NO.5-7, and the light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 of which the amino acid sequences are respectively shown as SEQ ID NO.8-10. The monoclonal antibody can specifically recognize the HA protein in an indirect immunofluorescence test, a protein immunoblotting test and a neutralization test. Besides, the monoclonal antibody can be subjected to a specific hemagglutination inhibition reaction with H5Nx subtype avian influenza viruses such as H5N1, H5N6, H5N8 and the like of different HA gene evolution branches such as 2.3. 2.1 d, 2.3. 4.4 b, 2.3. 4.4 d and the like, which indicates that the epitope recognized by the 1G10 monoclonal antibody is a broad-spectrum neutralizing epitope of the H5 subtype avian influenza viruses. Through a chick embryo immune escape test and sequence alignment, the neutralizing antigen epitope identified by the 1G10 monoclonal antibody is screened and contains 170th and 231th amino acid sites of HA protein, and the mutation of the neutralizing antigen epitope significantly influences antigenicity.
Owner:YANGZHOU UNIV

Multi-epitope fusion protein based on porcine rotavirus VP7 and VP8 double targets as well as preparation method and application of multi-epitope fusion protein

The invention discloses a multi-epitope fusion protein based on porcine rotavirus VP7 and VP8 double targets as well as a preparation method and application of the multi-epitope fusion protein. According to the invention, salmonella typhimurium flagellin FliCS.T is taken as a skeleton, dominant neutralizing epitopes of VP7 and VP8 are accurately integrated, and the multi-epitope fusion antigen FliCS.T-VP7 + VP8 is constructed. The fusion protein has two immunological advantages: an FliCS.T skeleton has TLR5 adjuvant activity, so that innate immunity and adaptive immunity of a host can be efficiently activated; key neutralizing epitopes of porcine rotaviruses VP7 and VP8 are synchronously presented through a multi-epitope strategy, and high-titer specific neutralizing antibody and potent cellular immune response aiming at two structural proteins can be induced in vivo. The invention provides the multi-epitope fusion antigen of the porcine rotavirus, which integrates high immunogenicity and broad-spectrum neutralization protection, and a feasible technical scheme is provided for prevention and control of the porcine rotavirus.
Owner:YANGZHOU UNIV

Porcine rotavirus VP8 protein dominant B cell neutralizing epitope peptide, multi-epitope fusion protein and application thereof

The invention discloses a porcine rotavirus VP8 protein dominant B cell neutralizing epitope peptide, a multi-epitope fusion protein and application of the multi-epitope fusion protein. The FliCS.T-VP8 multi-epitope fusion protein prepared by the invention is a multi-epitope fusion protein which takes salmonella typhimurium flagellin FliCS.T as a molecular skeleton and integrates the dominant B cell neutralizing epitope of the VP8 protein of the porcine rotavirus. According to the design, immunodominance epitope screening, multi-epitope fusion protein construction and genetic engineering technologies are fused, and the immunogenicity and immune protection efficacy of the fusion protein are remarkably enhanced. The FliCS.T-VP8 multi-epitope fusion protein not only can effectively induce high-level VP8 protein specific antibody response and cellular immune response, but also shows good porcine rotavirus neutralizing activity. In addition, the fusion protein has relatively high safety and stability, and has the potential of being used as an efficient subunit vaccine for preventing and controlling porcine rotavirus infection in the pig industry.
Owner:YANGZHOU UNIV

A broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis and its preparation method

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).
Owner:TIANJIN RINGPU BIO TECHNOLOGY CO LTD

High-stability and informatization-adaptive chemiluminescence mixing indoor quality control product for infectious disease project and preparation method of high-stability and informatization-adaptive chemiluminescence mixing indoor quality control product

The invention discloses a high-stability and informatization-adaptive chemiluminescence mixed indoor quality control product for infectious disease projects and a preparation method thereof. The method is characterized in that inactivated healthy human serum is used as a non-infectious optimized matrix, a single kit covers all infectious disease A and B immunodetection items specified by the National Health Committee, and three concentration gradients of negative, weak positive and strong positive are set. Through cooperation of a recombinant non-neutralizing epitope antigen, a high-specificity monoclonal antibody and a double-blocking system, interference-free coexistence of multiple items is realized, and the cross reaction rate is less than or equal to 1.0%; a four-dimensional synergistic compound long-acting stable system is adopted, and it is ensured that the activity retention rate is larger than or equal to 95.0% after 24 months of storage at 2-8 DEG C. The product is packaged in a special direct on-machine test tube, is matched with a fixed identity code of a pre-associated laboratory information system, supports two-way communication with an automatic instrument, and realizes no manual intervention in the whole process of quality control. The preparation process is standardized, is suitable for clinical laboratories of all levels of medical institutions, and promotes import and substitution of high-end quality control products.
Owner:李建红

Senecavirus type A nanoparticle antigen and application thereof in preparation of nanoparticle vaccine

The invention belongs to the technical field of preparation of veterinary vaccines, and particularly relates to a Senecavirus type A nanoparticle antigen and application thereof in preparation of a nanoparticle vaccine. According to the invention, a general Th cell epitope is fused with a highly conservative B cell neutralizing epitope VP2150-160aa of a three-copy Senecavirus A capsid protein, and the fused recombinant protein is displayed on the surface of a nanoparticle, so that the Senecavirus A nanoparticle antigen is finally constructed. The Senecavirus A nanoparticle vaccine is prepared from the Senecavirus A nanoparticle antigen, and the Senecavirus A nanoparticle vaccine can display more antigens at a time, so that the immunogenicity of the vaccine can be improved, and the immune effect of the vaccine can be enhanced.
Owner:HUAZHONG AGRI UNIV

Universal influenza virus-like particle vaccine based on glycosylation engineering optimization and preparation method and application thereof

PendingCN123082916AAntigenStable cell line
This invention discloses a universal influenza virus-like particle (VLP) vaccine based on glycosylation engineering optimization, its preparation method, and its application, belonging to the field of biomedical technology. The vaccine contains an S399 glycosylated mutant of the HA stem, a NA-HA1 fusion protein, and a Gag-5M2e fusion protein containing M2e tandem variants of five influenza subtypes, prepared by expression in a stable CHO-S cell line. Using the broad-spectrum neutralizing antibody CR9114 as a target, the S399 mutant was obtained through molecular docking screening. A vector was constructed using the PhiC31 integration system, and stable cell lines were screened. Expression was optimized through temperature control and ManNAc glycosylation, combined with Core700 size exclusion chromatography and heparin affinity chromatography for purification, resulting in high recovery. The obtained VLP showed 41.13% assembly integrity, a molecular weight of 4.27 MDa, a particle size of 120-124 nm, and good homogeneity. The vaccine is designed to deliver broad-spectrum neutralizing epitopes and multiple subtype antigens, with potential cross-protective efficacy against H9N2, H1N1, H3N2, H7N9, and H5N1. It is suitable for the prevention and control of avian influenza in poultry and for public health influenza reserves, providing a new solution for the large-scale production of broad-spectrum influenza vaccines.
Owner:KUNMING UNIVERSITY

Preparation method and application of monoclonal antibody based on recombinant goose circovirus Cap protein

The invention discloses a preparation method and application of a monoclonal antibody based on recombinant goose circovirus Cap protein, and belongs to the technical field of biology. The monoclonal antibody prepared based on the recombinant goose circovirus Cap protein has excellent specificity and affinity, has excellent reactivity with the goose circovirus, and also has high specificity and sensitivity when being applied to preparation of diagnostic reagents. Besides, the prepared monoclonal antibody is applied to non-therapeutic purpose neutralization virus activity and passive immune activity, and the monoclonal body can block the infection mechanism by combining virus key protein (Cap protein); the antibody targets the neutralizing epitope of the virus capsid protein and inhibits virus replication; instant immune protection can be provided by directly injecting the monoclonal antibody, interaction with virus protein can be achieved, neutralizing epitopes can be accurately positioned, vaccine design can be guided, the monoclonal antibody can be used for quantitative detection of the antibody level after vaccine immunization, and the monoclonal antibody has important significance in virus diagnosis and illness state evaluation.
Owner:FOSHAN UNIVERSITY

A broad-spectrum non-neutralizing antibody to foot-and-mouth disease virus and its use in the preparation of reagents for enhancing the induction of neutralizing antibodies

This invention provides a broad-spectrum non-neutralizing antibody against foot-and-mouth disease virus (FMD) and its application in the preparation of reagents that enhance the production of neutralizing antibodies, belonging to the field of antibody technology. The FMD virus broad-spectrum non-neutralizing antibody has the amino acid sequence of its heavy chain variable region as shown in SEQ ID NO:1 and the amino acid sequence of its light chain variable region as shown in SEQ ID NO:2. This invention utilizes single B-cell antibody technology to screen and obtain a porcine broad-spectrum non-neutralizing monoclonal antibody SP1C6, which can recognize a conformational epitope on VP2. The broad-spectrum non-neutralizing antibody SP1C6 increases the level of neutralizing antibodies induced by FMD virus in pigs by blocking the non-neutralizing epitopes of the FMD virus antigen.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Recombinant bacillus subtilis with PEDV S protein and intestinal mammary gland axis key presenting cell targeting peptide displayed on surface and application of recombinant bacillus subtilis

The invention discloses a recombinant expression vector as well as a construction method and application thereof. The invention also discloses a recombinant strain as well as a construction method and application thereof. The invention also discloses a genetic engineering live vector vaccine. According to the invention, probiotic bacillus subtilis is used as an antigen delivery carrier, and recombinant bacillus subtilis for recombinant integration tandem expression of porcine epidemic diarrhea virus antigen neutralizing epitopes and intestinal M cell and dendritic cell (DCs) targeting peptides is constructed. The recombinant live vector vaccine is orally taken and immunized by sows, and efficient intestinal mucosa immune protection is provided for piglets in the lactation period by enhancing the intestinal mammary axial function of the sows, so that a safe, simple and convenient immune way is provided for effectively preventing the occurrence of epidemic diarrhea of the piglets.
Owner:NANJING AGRICULTURAL UNIVERSITY

B cell neutralizing epitope on the surface of African swine fever virus outer envelope protein p12 and its screening and verification method and application

ActiveCN118620037BScreening method is specific and convenientVirus peptidesImmunoglobulins against virusesPulmonary MacrophagesCell
The present invention discloses a neutralizing epitope in the B cell of the p12 protein surface of the outer envelope of African swine fever virus (ASFV), and a screening and verification method and application thereof, and specifically discloses two screened B cell epitopes GN08 and MA11 in the p12 protein of the outer envelope of ASFV, wherein the hybridoma cell (preservation number CCTCC NO: C2023192) produced by the monoclonal antibody against the epitope GN08, the cell supernatant secreted by the hybridoma cell and the mouse-derived ascites are verified to have the activity of neutralizing the ASFV virus by using the cell neutralization test of the primary lung macrophage (PAM) of the pig infected with the ASFV virus, while the cell supernatant secreted by the hybridoma cell against the MA11 epitope and the mouse-derived ascites do not have the activity of neutralizing the ASFV virus. Therefore, the GN08 epitope is a neutralizing epitope of the B cell on the surface of the p12 protein of the outer envelope of ASFV, and has the application potential of being developed into a neutralizing virus epitope target.
Owner:YANGZHOU UNIV

A reconstituted respiratory syncytial virus f protein trimer

The application discloses a reconstructed respiratory syncytial virus F protein trimer, and relates to the technical field of genetic engineering vaccines.The application designs a RSV F protein trimer, the monomer of the trimer does not contain a p27 sequence, and a furin enzyme cleavage peptide segment aa110-aa136 is deleted; a GS linker is used for connecting between an F2 domain and an F1 domain; the application also designs point mutation combinations, the point mutation combinations can form inter-chain disulfide bonds, so that covalent connection of the trimer is realized, and the problem of trimer depolymerization is fundamentally solved; the trimer is stably kept in a pre-F state, and there is no post-F-like structure; an ELISA result shows that neutralizing epitopes are completely retained; a thermal acceleration experiment method is used to challenge the trimer antigen structure, and the result shows that the trimer antigen purity reaches more than 95% after being placed at 37 DEG C for 28 days, and the stability is very good; the trimer is used to prepare a vaccine, and the vaccine can meet the standard of a regulation requirement without freeze drying.
Owner:BEIJING LUZHU BIOTECH +1

A monoclonal antibody against bovine coronavirus S2 protein, its antigenic epitopes, and its applications.

This invention relates to the field of biomedical technology, and in particular to a monoclonal antibody against bovine coronavirus S2 protein, its antigenic epitope, and its applications. The invention provides a monoclonal antibody against bovine coronavirus S2 protein, prepared from a hybridoma cell line with accession number CCTCC NO: C202510. The amino acid sequence of the antigenic epitope recognized by the monoclonal antibody is shown in SEQ ID NO:1. Experiments have confirmed that this monoclonal antibody possesses neutralizing activity, and its targeted epitope is a key neutralizing epitope. This invention provides new strategies and tools for the development of antibody drugs and vaccines for bovine coronavirus, as well as for diagnostic testing.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

Application of antigen gene and polypeptide thereof in prevention of canine parvovirus disease

The invention discloses an application of an antigen gene and a polypeptide thereof in preventing canine parvovirus disease. The antigen polypeptide provided by the invention can be used as a neutralizing epitope vaccine; the neutralizing epitope vaccine is a protein consisting of 207 amino acid residues; a gene for coding the antigen polypeptide contains 621 nucleotides. The antigen polypeptide provided by the invention, namely the neutralizing epitope vaccine, has the advantages of strong antigenicity, good prevention effect, safety, high yield and the like, and provides a new choice for prevention of canine parvovirus diseases.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Vector vaccine based on human-derived horseshoe-shaped protein skeleton

The invention discloses a vector vaccine based on a human-derived horseshoe-shaped protein skeleton. The vector vaccine is formed by displacing neutralizing epitope peptide into an alpha helical structural domain of a human-derived horseshoe-shaped protein. The vector vaccine can induce efficient, specific, lasting and broad-spectrum neutralizing antibody reaction, has the characteristics of low autoimmunogenicity, high safety and the like, and is expected to be used as a safe, stable and efficient novel epitope vaccine.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

An RSVpre-F trimeric protein combination and its application in the preparation of a bivalent RSV vaccine

ActiveCN121203039BDisulfide bondingAdjuvant
This invention discloses an RSV pre-F trimer protein combination and its application in the preparation of a bivalent RSV vaccine, relating to the field of human vaccine technology. The vaccine is prepared by mixing equal masses of RSV-A and RSV-B subtype pre-F trimer proteins and adding 0.35 mg / 0.5 mL of aluminum hydroxide adjuvant. Both F proteins have their p27 fragment and C-terminal esterification region deleted, and F2 / F1 are linked by GSGSGS. Interchain disulfide bonds are introduced at S146C / N460C and A149C / Y458C sites, and intrachain disulfide bonds are introduced at S155C / S290C sites. After secretion and expression by CHO cells, the pre-F trimer spontaneously assembles into a stable pre-F trimer. The vaccine does not require lyophilization and maintains high purity and the integrity of neutralizing epitopes after storage at 37°C for 28 days. It can significantly induce neutralizing antibodies and T-cell immunity and can be used to prevent various RSV-A / B infections.
Owner:BEIJING LUZHU BIOTECH

ELISA antibody detection kit coated with neutralizing epitope protein fragment of pseudorabies virus, and vaccine composition containing the same

The present invention provides an ELISA antibody detection kit for neutralizing antibodies of porcine pseudorabies virus, the kit comprising a support medium coated with a protein fragment of a neutralizing epitope of the gD protein of the porcine pseudorabies virus, an enzyme-labeled secondary antibody reagent, a detection reagent for reacting to the enzyme-labeled secondary antibody, a negative control and a positive control; the protein fragment of the neutralizing epitope of the gD protein of the porcine pseudorabies virus is shown in SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5. The ELISA antibody detection kit of the present invention can be used to evaluate the neutralizing antibody titer produced by vaccines prepared from different strains of porcine pseudorabies virus, so as to evaluate the effects of different vaccines after immunization, and also helps to formulate a scientific immunization program in a timely manner according to the test results. The present invention also provides a vaccine composition containing an immunizing amount of the protein fragment of the neutralizing epitope of the gD protein of the porcine pseudorabies virus, which has a neutralizing effect on strains of different types of PRV (including original vaccine strains, classical strains, and variant strains).
Owner:LUOYANG PULIKE WANTAI BIOTECH

Recombinant antigens for american trypanosomiasis and methods of making and using the same

PendingCN122628221Anot easily disturbedStrong specificityAntigenTrypanosomiasis
The application belongs to the technical field of biotechnology, and particularly relates to a recombinant antigen of American trypanosomiasis and a preparation method and application thereof. The application provides a recombinant antigen of American trypanosomiasis, wherein a plurality of neutralizing epitopes and complete amino acid sequences of Trypanosoma cruzi antigens are connected according to a specific order to construct a recombinant antigen capable of covering all stages of the life cycle of Trypanosoma cruzi. The recombinant antigen is complete in Chagas antibody recognition site coverage, can recognize and combine all types of antibodies in the Chagas chronic and acute infection period, and is not easily interfered by other substances in serum, and is high in specificity.
Owner:SHENZHEN YHLO BIOTECH

ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen and its preparation and application

The present invention discloses an ETEC pilus protein chimeric PEDV spike protein multi-epitope fusion antigen and its preparation and application. The fusion antigen uses the Escherichia coli K88 pilus FaeG protein as a skeleton protein and is obtained by replacing the non-neutralizing epitope on the FaeG protein with the neutralizing epitope of the PEDV spike protein. The fusion antigen prepared by the present invention effectively displays the PEDV spike protein epitope on the FaeG skeleton protein and can be recognized by porcine epidemic diarrhea virus-specific antibodies, which is of great significance for the development of a broad-spectrum multivalent vaccine for porcine diarrhea.
Owner:SHANXI AGRI UNIV

Porcine rotavirus vp7 and vp8 double-target based polyepitope fusion protein and preparation method and application thereof

The application discloses a multi-epitope fusion protein based on porcine rotavirus VP7 and VP8 double targets and a preparation method and application thereof. S.T As a skeleton, the advantages of precisely integrating VP7 and VP8 neutralizing epitopes are constructed into multi-epitope fusion antigen FliC S.T -VP7+VP8. The fusion protein has two immunological advantages: FliC S.T The skeleton has TLR5 adjuvant activity, can efficiently activate the innate immunity and adaptive immunity of a host, and can synchronously present key neutralizing epitopes of porcine rotavirus VP7 and VP8 through a multi-epitope strategy, so that high-titer specific neutralizing antibodies and strong cellular immune responses against the two structural proteins can be induced in the body. The application provides a multi-epitope fusion antigen of porcine rotavirus which integrates high immunogenicity and broad-spectrum neutralization protection, and provides a feasible technical scheme for the prevention and control of porcine rotavirus.
Owner:YANGZHOU UNIV

Small molecule surrogate for a neutralization epitope on the ZIKA virus envelope protein

PCT designated stageWO2025137264A9Zika virusVirus Binding
Provided herein are compositions including a binding reagent for a Zika virus (ZIKV) epitope, pharmaceutical compositions including such binding reagents, and methods of detecting ZIKV binding antibodies and ZIKV neutralizing antibodies in patients.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION +1

Application of antigen gene and polypeptide thereof in preventing goose parvovirus disease

The invention discloses an antigen gene and application of polypeptide thereof in preventing goose parvovirus disease. The antigen gene and the polypeptide provided by the invention can be used as a neutralizing epitope protein vaccine and a neutralizing epitope gene vaccine; the neutralizing epitope protein vaccine is a protein composed of 305 amino acid residues; a gene for coding the antigen polypeptide contains 918 nucleotides. The antigen gene and the polypeptide, namely the neutralizing epitope protein vaccine and the neutralizing epitope gene vaccine, provided by the invention have the advantages of strong antigenicity, capability of inducing an organism to generate a higher neutralizing antibody, good prevention effect, no pathogen transmission and the like, and a new situation is opened up in the GP prevention history.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Neutralizing epitope polypeptide of grouper nervous necrosis virus and application of neutralizing epitope polypeptide in serological diagnosis test paper

The invention provides a neutralizing epitope polypeptide of grouper nervous necrosis virus and application of the neutralizing epitope polypeptide in serological diagnosis test paper, and the amino acid sequence of the neutralizing epitope polypeptide is SEQ ID NO: 1 or SEQ ID NO: 2. On the other hand, the invention also provides a serological diagnosis test strip for the nervous necrosis virus disease of the grouper, wherein the NNV capsid protein neutralizing epitope polypeptide is used as a detection line. The antigen polypeptide used by the test strip is an NNV capsid protein neutralizing epitope specific fragment, the antigen recognition effect is improved by optimizing the mixing ratio, cross reaction with other pathogen positive serum of grouper is avoided, and the detection accuracy is ensured.
Owner:OCEAN UNIV OF CHINA

Methods, immunogens, compositions, and uses for identifying neutralizing epitopes in bovine coronavirus spike protein

ActiveCN121385299BDepsipeptidesMaterial analysisAntigen epitopeLinear epitope
The application provides a method for identifying neutralizing antigen epitopes in bovine coronavirus spike protein, immunogens, compositions and uses, relates to the technical field of biology, and specifically constructs an efficient neutralizing epitope identification route: online prediction, nanoparticle multivalent display, animal immunization, combined evaluation of binding and neutralization, which can screen out epitopes with neutralizing activity from candidate linear epitopes in a relatively short period of time; the multivalent presentation of ferritin nanoparticles significantly improves the detectability of the immune response of weak immunogenic linear peptides; the obtained epitopes can directly serve the development of subunit vaccines, multi-epitope nanovaccines and in vitro diagnostic reagents.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

Broad-spectrum mRNA vaccine for preventing cat infectious peritonitis and preparation method thereof

The invention provides a broad-spectrum mRNA vaccine for preventing feline infectious peritonitis and a preparation method thereof, the vaccine comprises an mRNA molecule 1 and an mRNA molecule 2, the mRNA molecule 1 comprises a self-assembled LS nanoparticle fusion sequence based on a neutralizing epitope of series FIPV type I S protein and a T cell epitope, and the mRNA molecule 2 comprises a self-assembled LS nanoparticle fusion sequence based on series FIPV type I S protein. The LS-FIBV-I MEV-N-M antigen protein coding sequence is composed of the antigen coding sequences of the N protein and the M protein; the mRNA molecule 2 comprises an antigen protein coding sequence which is fused and self-assembled by an FIPV II type S protein receptor structural domain RBD and has an LS nano-particle structure. According to the invention, through the combination of double mRNA molecules, while the ADE risk is avoided, the broad-spectrum protection of the FIPV type I and the FIPV type II is realized.
Owner:TIANJIN RINGPU BIO TECHNOLOGY CO LTD